Guidance for BioMarin Pharmaceutical Inc. (BMRN)
Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
---|---|---|---|---|---|---|
2024 | $2.75 – $2.95 | $2.75 | $2.70B – 2.80B | $2.76B | = Maintained | Details |
2024 | $2.60 – $2.80 | $2.83 | $2.70B – 2.80B | $2.82B | = Maintained | Details |
2023 | $1.80 – $2.05 | $1.61 | $2.38B – 2.50B | $2.58B | = Maintained | Details |
2023 | $1.90 – $2.05 | $2.19 | $2390.00M – 2470.00M | $2449.00M | = Maintained | Details |
2023 | $1.80 – $2.05 | $1.02 | $2.38M – 2.50M | $2.46M | = Maintained | Details |
2022 | N/A | N/A | $2.05M – 2.15M | N/A | = Maintained | Details |
2022 | N/A | N/A | $2.05B – 2.15B | $2.14B | = Maintained | Details |
2022 | N/A | N/A | $2.06B – 2.16B | $2.11B | = Maintained | Details |
2022 | N/A | N/A | $2.06B – 2.16B | $2.12B | = Maintained | Details |
2021 | N/A | N/A | $1.75B – 1.85B | $1.81B | = Maintained | Details |
2021 | N/A | N/A | $1.75B – 1.85B | $1.91B | Lowered | Details |
Q4 2021 | N/A | N/A | $1.82B – 1.88B | $1.85B | = Maintained | Details |
Q3 2021 | N/A | N/A | $1.75B – 1.85B | $1.82B | = Maintained | Details |
2020 | N/A | N/A | $1.95B – 2.05B | $1.95B | = Maintained | Details |
2020 | N/A | N/A | $1.85B – 1.95B | $1.97B | = Maintained | Details |
2020 | N/A | N/A | $1.85B – 1.95B | $1.90B | = Maintained | Details |
2020 | N/A | N/A | $1.81B – 1.87B | $1.86B | = Maintained | Details |
2019 | N/A | N/A | $1.68B – 1.75B | $1.73B | = Maintained | Details |
2019 | N/A | N/A | $1.68B – 1.75B | $1.70B | = Maintained | Details |
2019 | N/A | N/A | $1.69B – 1.72B | $1.70B | = Maintained | Details |
2018 | N/A | N/A | $1.47B – 1.53B | N/A | = Maintained | Details |
2018 | N/A | N/A | $1.47B – 1.53B | $1.48B | = Maintained | Details |
2018 | N/A | N/A | $1.47B – 1.53B | $1.51B | = Maintained | Details |
Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
2017 | N/A | N/A | $1.29B – 1.32B | $1.31B | = Maintained | Details |
Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
2016 | N/A | N/A | $1.05B – 1.10B | $1.15B | = Maintained | Details |
2016 | N/A | N/A | $1.10B – 1.15B | $1.09B | Raised | Details |
2015 | N/A | N/A | $880.00M – 900.00M | $897.92M | Raised | Details |
2015 | N/A | N/A | $885.00M – 915.00M | $880.60M | = Maintained | Details |
2013 | N/A | N/A | $530.00M – 555.00M | $562.80M | = Maintained | Details |
2012 | N/A | N/A | $465.00M – 510.00M | $512.60M | = Maintained | Details |
2012 | N/A | N/A | $475.00M – 510.00M | $494.51M | = Maintained | Details |
2012 | N/A | N/A | $475.00M – 510.00M | $487.87M | Raised | Details |
2011 | N/A | N/A | $436.00M – 465.00M | $441.08M | Raised | Details |
2011 | N/A | N/A | $417.00M – 452.00M | $456.30M | = Maintained | Details |